# dMR During First Line Treatment of Non Squamous Lung Cancer: Time Course and Prognostic and Predictive Impact.

> **NCT02195336** · NA · UNKNOWN · sponsor: **Karl Kölbeck** · enrollment: 20 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DEVICE:** dMRT
- **DRUG:** Bevacizumab
- **DRUG:** paclitaxel and carboplatin

## Key facts

- **NCT ID:** NCT02195336
- **Lead sponsor:** Karl Kölbeck
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-08
- **Primary completion:** 2016-06
- **Final completion:** 2018-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2014-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02195336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02195336, "dMR During First Line Treatment of Non Squamous Lung Cancer: Time Course and Prognostic and Predictive Impact.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02195336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*